Median progression-free survival (mPFS) was 15.1 months, and the confirmed overall response rate (cORR) increased to 45% for the 100mg QD (once daily) tablet cohort in an updated analysis of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results